By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Navidea Biopharmaceuticals 

425 Metro Place Northurt
Suite 400
Dublin  Ohio  43017  U.S.A.
Phone: 614-793-7500 Fax: 614 793 7520


Medical Device

Company News
Navidea Biopharmaceuticals (NAVB) Announces Second Quarter 2014 Financial Results; Total Revenues Grow To $1.1 Million 8/6/2014 9:29:58 AM
Navidea Biopharmaceuticals (NAVB) To Announce Second Quarter 2014 Financial Results On August 6, 2014 7/29/2014 9:48:47 AM
Navidea Biopharmaceuticals (NAVB) Announces 2014 Annual Meeting Results 7/18/2014 10:11:05 AM
Navidea Biopharmaceuticals (NAVB) Joins Essex Woodland’s Rheumco To Develop Radiopharmaceuticals For Detection And Treatment Of Arthritic Diseases 7/16/2014 9:38:38 AM
Navidea Biopharmaceuticals (NAVB) To Webcast Investor Briefing On Sentinel Lymph Node Biopsy In Head & Neck Cancers July 8, 2014 7/3/2014 6:41:28 AM
Navidea Biopharmaceuticals (NAVB) To Present At The 9th Annual JMP Securities Healthcare Conference 6/18/2014 11:23:51 AM
Navidea Biopharmaceuticals (NAVB) Release: FDA Approves Lymphoseek To Help Determine The Extent Of Head And Neck Cancer In The Body 6/13/2014 9:58:39 AM
Navidea Biopharmaceuticals (NAVB)’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation In Tumor-Positive Sentinel Lymph Nodes In Post-Hoc Analysis 6/11/2014 8:09:25 AM
Navidea Biopharmaceuticals (NAVB) Announces Positive Lymphoseek® (Technetium Tc 99m Tilmanocept) Injection Results On Injection Timing And Surgery Across Multiple Solid Tumor Types 6/11/2014 6:30:37 AM
Navidea Biopharmaceuticals (NAVB) Announces Data Demonstrating Potential Of Manocept™ Platform To Diagnose Rheumatoid Arthritis And Kaposi's Sarcoma 6/10/2014 6:47:53 AM